All Type of News
Classified(?) change process of emergency contraception to OTC
As the Ministry of Food and Drug Safety(MFDS) has started to review the change of ‘emergency contraception(morning after pill)’ to OTC even without the process of collecting public opinions, the medical industry has e...
Love of foreign pharmacy customers on Chungsimwon, medicated patches and toothpastes
The pharmacy field, where foreign workers and tourists visits during holiday seasons, gets busy fulfilling specific products.
This is because not only foreign workers, but tourists from other countries, such as China...
Adcetris, an ADC, receives the health insurance benefit exempted from total amount limit
An antibody-drug conjugate(ADC) has overcame the wall of the health insurance benefit. It also did not get restricted by the total amount limit of the economic evaluation exception.
The Health Insurance Review & Asse...
Boehringer’s approved ‘Jardiance Duo’ fuels competition among SGLT-2 complexesIn the SGLT-2-inhibitor antidiabetic treatment market led by AstraZeneca’s ‘Forxiga(dapagliflozin)’ by itself, competition is expected among complexes.
According to the industr...
|
Asia-Pacific countries including Korea are expected to enlarge generic shares
It was diagnosed the proportion of generic products is increasing in most Asia-Pacific regions and the trend will continue in the future.
According to the ‘Patent Cliff and Asian Generic Products’ Present and Future ...
Harvoni registers its name in the pharmaceutical patent list
Harvoni Tab(sofosbuvir, ledipasvir), a hepatitis C treatment, register its name in the pharmaceutical patent list.
In the Ministry of Food and Drug Safety’s ‘Pharmaceutical Patent List,’ Gilead Sciences Korea was kno...
Ilyang Pharmaceutical launches ‘Supect’ as a primary treatment of leukemia‘Supect(generic name: radotinib),’ the Asia’s first leukemia treatment developed by Ilyang Pharmaceutical(CEO Dong-yeon Kim), will be launched as the ‘primary treatment’ on the ...
|
Creations of health insurance benefits for NOAC Lixiana
While the use of novel oral anticoagulants(NOAC) has steadily increased, ‘Lixiana’ is expected to be applied by the health insurance benefit.
On the 19th, the Ministry of Health and Welfare announced it will establis...
Sovaldi and Harvoni land on 13 hospitals and start to be supplied
Prescriptions of ‘Sovaldi(sofosbuvir),’ a large hepatitis C treatment, and ‘Harvoni(sofosbuvir and ledipasvir),’ a complex, have started in the domestic market.
Gilead Sciences Korea announced supply of the two oral ...
Significant achievement of the Yuhan anb Boehringer duo in the outpatient prescription marketWhile the domestic outpatient prescription market has been depressed since the pharmaceutical price cuts in 2012, the top company ranking has met many changes.
Some of the top ...
|
